Alimera Sciences

Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Our commitment to retina specialists and their patients is manifest in our product portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion.
Alimera Sciences’ management team has a strong track record of product discovery, development and revenue growth in the ophthalmic pharmaceutical industry and are dedicated and focused to making Alimera a leading ophthalmic biopharmaceutical company. Our team has demonstrated expertise through the extensive development and commercialization of ophthalmic products. Our strategy behind Alimera is to:
Bring to market ILUVIEN ®, recently granted marketing authorization in Austria, France, Germany, Portugal, Spain and the United Kingdom as “ILUVIEN ® 190 micrograms intravitreal implant in applicator Fluocinolone Acetonide”, for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. ILUVIEN is now undergoing the national phase of the review process in Italy. Alimera Sciences is still seeking approval in the United States.
Continue evaluating ILUVIEN for other ophthalmic indications. Learn More
Evaluate the use of NADPH Oxidase inhibitors for ophthalmic diseases
Pursue the development, license or acquisition of rights to potential ophthalmic drug delivery technologies and compounds.
Operate as an ethically driven company, recognizing our responsibility to others and the importance of having a positive impact on those with whom we interact.